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Erika Hamilton1, Kimberly Blackwell1, Amy C Hobeika2, Timothy M Clay3, Gloria Broadwater4, Xiu-Rong Ren5,
Wei Chen5, Henry Castro3, Frederic Lehmann3, Neil Spector1, Junping Wei6, Takuya Osada6, H Kim Lyerly2
and Michael A Morse1*Corrections
In our original manuscript [1], the corresponding author,
Michael A Morse, was missed from the authors’ list.
Therefore the correct author list should be:
Erika Hamilton, Kimberly Blackwell, Amy C Hobeika,
Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei
Chen, Henry Castro, Frederic Lehmann, Neil Spector,
Junping Wei, Takuya Osada, H Kim Lyerly and Michael
A Morse.
Also the title of our original manuscript ‘Phase 1 clinical
trial of HER2-specific immunotherapy with concomitant
HER2 kinase inhibtion’ is also incorrect. The title should
read:‘Phase 1 clinical trial of HER2-specific immunotherapy
with concomitant HER2 kinase inhibition’.
Journal of Translational Medicine regret any inconveni-
ence that this inaccuracy might have caused.
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